Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years ...

The majority — 62 percent — said they were using the drugs to treat a chronic condition like diabetes or heart disease while ...

A new poll found that one in eight American adults had used a GLP-1 drug, with half of those people still taking the ...

Unregulated use of fentanyl and overdose deaths have increased dramatically in recent years, and this trend was made more ...

One case involved a female, age 42, with a history of bipolar I disorder, post-traumatic stress disorder (PTSD), morbid ...

Researchers are looking to see if GLP-1 receptor agonists, DPP4 inhibitors, and SGLT2 inhibitors have beneficial effects in ...

The global GLP-1 receptor agonist market is poised for remarkable expansion in the coming decade, according to a recent market analysis. Projections suggest an impressive surge from US$ 23,854.53 ...

Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim ...

TAAR1 can couple to diverse G protein subtypes, including Gs, Gq and Gi. Shandong University investigators have recently reported the discovery of a novel TAAR1 agonist as an antipsychotic drug ...

which evaluates Denali’s eIF2B agonist DNL343. "We are excited to move to the next phase of Regimen G and evaluate the effects of DNL343,” said Merit Cudkowicz, MD, MSc, principal investigator ...

Hundreds of thousands of people worldwide are taking drugs like Ozempic to lose weight. But what do we actually know about ...